Isochromosome 17q in Chronic Lymphocytic Leukemia

Area of Science:

• Hematology
• Oncology
• Cytogenetics

Background:

• Acquired cytogenetic abnormalities in chronic lymphocytic leukemia (CLL) aid prognosis.
• TP53 gene deletion in CLL signifies aggressive disease, poor prognosis, and treatment resistance.
• Standard cytogenetics may miss TP53 deletions, necessitating techniques like interphase fluorescence in situ hybridization (iFISH).

Purpose of the Study:

• To investigate if the presence of isochromosome i(17q) in CLL patients with TP53 deletion identifies a subgroup with a more adverse prognosis.
• To explore the prognostic significance of i(17q) in conjunction with TP53 deletion in CLL.

Main Methods:

• Analysis of 150 chronic lymphocytic leukemia (CLL) cases.
• Detection of TP53 deletion using interphase fluorescence in situ hybridization (iFISH).
• Assessment for the presence of isochromosome i(17q) in conjunction with TP53 deletion.

Main Results:

• TP53 deletion was identified in 12% (18/150) of the studied CLL cases.
• Approximately 33% (6/18) of CLL cases with TP53 deletion also exhibited i(17q).
• Cases with i(17q) showed a trend towards increased associated chromosomal aberrations.

Conclusions:

• Isochromosome i(17q) may identify a distinct subgroup of CLL patients with TP53 deletion.
• The presence of i(17q) might represent a more adverse prognostic marker than TP53 deletion alone in CLL.
• Further studies are warranted to confirm the prognostic value of i(17q) in CLL with TP53 deletion.